Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of nimotuzumab with radiotherapy and chemotherapy for advanced or recurrent oral and oropharyngeal squamous cell carcinoma
ChiCTR1900021853Phase 4Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nimotuzumab in Oral Mucosal Carcinoma and oropharyngeal squamous cell carcinoma (OPSCC) (4 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: overall survival at 5 years. Started May 2019; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on ChiCTR1900021853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021853.